(Q39177270)

9 September 2017

Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha (English)

1 reference

9 September 2017

5

0 references

Markus H Heim

10

0 references

Joachim Lupberger

object named as

Joachim Lupberger

1

0 references

Thomas F Baumert

11

object named as

Thomas F Baumert

1 reference

9 September 2017

8

Patrick Pessaux

1 reference

9 September 2017

9

Mirjam B Zeisel

1 reference

9 September 2017

6

Christine Thumann

1 reference

9 September 2017

François H T Duong

2

1 reference

9 September 2017

Isabel Fofana

3

1 reference

9 September 2017

Laetitia Zona

4

1 reference

9 September 2017

Sarah C Durand

7

1 reference

9 September 2017

language of work or name

English

0 references

publication date

5 September 2013

1 reference

9 September 2017

1 reference

9 September 2017

58

1 reference

9 September 2017

4

1 reference

9 September 2017

1225-1235

1 reference

Interferon signaling in the liver during hepatitis C virus infection.

9 September 2017

1 reference

HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons

21 January 2018

1 reference

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA

21 January 2018

1 reference

Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus

21 January 2018

1 reference

Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector

21 January 2018

1 reference

Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol

21 January 2018

1 reference

Regulation of liver regeneration by growth factors and cytokines

21 January 2018

1 reference

Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling.

21 January 2018

1 reference

Epidemiology of viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

Anti-hepatitis C virus drugs in development

21 January 2018

1 reference

New virologic tools for management of chronic hepatitis B and C

21 January 2018

1 reference

Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.

21 January 2018

1 reference

Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling

21 January 2018

1 reference

Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response

21 January 2018

1 reference

Interferon signaling and treatment outcome in chronic hepatitis C

21 January 2018

1 reference

Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication.

21 January 2018

1 reference

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

21 January 2018

1 reference

Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.

21 January 2018

1 reference

Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry

21 January 2018

1 reference

New targets for antiviral therapy of chronic hepatitis C.

21 January 2018

1 reference

HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.

21 January 2018

1 reference

Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies

21 January 2018

1 reference

Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.

21 January 2018

1 reference

Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection

21 January 2018

1 reference

Ephrin receptor: a door to KSHV infection.

21 January 2018

1 reference

Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection

21 January 2018

1 reference

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network.

21 January 2018

1 reference

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells

21 January 2018

1 reference

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras

21 January 2018

1 reference

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals

21 January 2018

1 reference

A three-dimensional model to analyze drug-drug interactions

21 January 2018

1 reference

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation

21 January 2018

1 reference

Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

21 January 2018

1 reference

Chemical probes that competitively and selectively inhibit Stat3 activation

21 January 2018

1 reference

STAT3 negatively regulates type I IFN-mediated antiviral response.

21 January 2018

1 reference

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

21 January 2018

1 reference

Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha

21 January 2018

1 reference

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Treatment of non-small-cell lung cancer with erlotinib or gefitinib

21 January 2018

1 reference

Boceprevir for chronic HCV genotype 1 infection

21 January 2018

1 reference

Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein

21 January 2018

1 reference

7 January 2021

Peginterferon plus adefovir versus either drug alone for hepatitis delta

1 reference

7 January 2021

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway

1 reference

7 January 2021

Hepatitis C: Host receptor tyrosine kinases mediate HCV entry and are a promising new target for antiviral therapy

1 reference

7 January 2021

1 reference

7 January 2021

Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.26404

1 reference

9 September 2017

1 reference